The Board of Directors today in their meeting considered and approved the audited financial results for quarter and year ended 31st March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Brawn Biotech Ltd reported a turnaround from loss to profit for FY26. Total revenue grew 28.5% to Rs 1,743.18 Lakhs from Rs 1,355.83 Lakhs in FY25. Revenue from operations increased to Rs 1,697.77 Lakhs from Rs 1,346.50 Lakhs. The company posted a net profit of Rs 94.06 Lakhs compared to a net loss of Rs 179.81 Lakhs in the previous year. Basic and diluted EPS stood at Rs 3.26 versus negative Rs 5.87 in FY25. However, operating profit remains razor thin at just Rs 0.11 Lakhs, with a net tax credit of Rs 93.95 Lakhs contributing significantly to the bottom line. The auditor issued an unmodified opinion on the financial statements.
The company has returned to profitability after two consecutive loss-making years, which is a positive sign. However, the slim operating profit despite revenue growth and reliance on tax credit for bottom-line profit raises questions about operational efficiency and cost structure. Shareholders should monitor whether the company can improve its operating margins going forward.